KARYOPHARM THERAPEUTICS INC (KPTI)
Health Care · Biotechnology · NASDAQ
Karyopharm Therapeutics develops novel cancer therapies using its proprietary XPO1 inhibition platform, with the lead drug XPOVIO currently used in multiple myeloma and a late-stage pipeline targeting myelofibrosis.
What KARYOPHARM THERAPEUTICS INC does
Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of small-molecule medicines for cancer. Its primary technology involves XPO1 inhibition, which forces the nuclear retention of tumor suppressor proteins and oncoprotein mRNAs to trigger apoptosis in malignant cells. The company currently markets XPOVIO (selinexor) for multiple myeloma and is advancing clinical programs for myelofibrosis and other malignancies.
Recent developments
In August 2026, the company confirmed it remains on track to submit an sNDA for selinexor in combination with ruxolitinib for myelofibrosis under the FDA's Accelerated Approval pathway. The company reported Phase 3 SENTRY trial results for this indication while also announcing that its Phase 3 XPORT-EC-042 trial in endometrial cancer did not meet its primary endpoint.
From KARYOPHARM THERAPEUTICS INC's filing of 2026-08-13.
Themes: oncology, targeted cancer therapy, XPO1 inhibition, multiple myeloma, myelofibrosis, orphan drugs
Fundamentals
- Price$0.3586 as of 2026-10-20 close
- Market cap$8M as of 2026-08-06 (share count; price 2026-10-20)
- 1-year return-94.5% 2025-10-20 close $6.47 → 2026-10-20 close $0.3586
- P/En/a negative earnings
- Net margin-134.2% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing reports debt under a line we do not read, so a total would be understated.
- Revenue growth (YoY)+0.6% FY2025, SEC XBRL
- Revenue CAGR (3y)-2.4% SEC XBRL
- Beta0.80 as of 2026-09-02
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How KPTI compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $33M | -$23M | -$67M | -$2.32 | -$25M† | — |
| Q1 FY2026 2026-03-31 | $35M | -$27M | -$22M | -$1.24 | -$23M | — |
| Q4 FY2025 2025-12-31 | $34M† | -$18M† | -$102M† | -$7.00† | -$12M† | $0† |
| Q3 FY2025 2025-09-30 | $44M | -$15M | -$33M | -$3.82 | -$6M† | $0† |
| Q2 FY2025 2025-06-30 | $38M | -$24M | -$37M | -$4.32 | -$19M† | $0† |
| Q1 FY2025 2025-03-31 | $30M | -$33M | -$23M | -$2.77 | -$39M | $0 |
| Q4 FY2024 2024-12-31 | $31M† | -$31M† | -$31M† | -$3.60† | -$26M† | -$53000† |
| Q3 FY2024 2024-09-30 | $39M | -$26M | -$32M | -$3.85 | -$19M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$55M
- Short-term investments$10M
- Total debtnot shown the filing reports its long-term debt in a form we do not read yet
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How KARYOPHARM THERAPEUTICS INC looks technically
KARYOPHARM THERAPEUTICS INC (KPTI) is trading 94.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 46 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 63, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 19, in oversold territory (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 96.7% below its highest point of the past year. Trading volume is unusually light — only about 49% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 94.3% below its 200-day average, the long-term trend line — a long-term downtrend | -94.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.44 | $1.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.31 | $6.31 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 1.93. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 46 trading days ago — a "death cross", a bearish long-term signal | 46 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 63, with sellers in control | 63.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 19, in oversold territory (below 30) | 18.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.31 to $1.20) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 5.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.99 | $10.99 |
|---|---|---|
| From the 52-week high | it is 96.7% below its 52-week high (its highest price of the past year) | -96.7% |
| Above the 52-week low | it is 15.7% above its 52-week low (its lowest price of the past year) | +15.7% |
| Below the 52-week high | it is 96.7% below its highest point of the past year | 96.7% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $731.42 (set on 2014-12-08) | $731.42 |
| Given back of the 52-week move | over the past year its closes ranged ($0.315 to $10.67), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.71 to $7.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.4% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 400.6% below a resistance level at $1.79 — a price it turned at twice since 2026-07-31, most recently on 2026-08-17. Since 2024-10-21 it has 0 such levels below the current price and 19 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +400.6% |
| All-time low | its lowest closing price on record is $0.31 (set on 2026-10-15) | $0.31 |
| Above the all-time low | it is 15.7% above its all-time low | +15.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 92% of the past ~6 months) | 92nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1349 between its high and its low — about 37.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1349 |
| Bollinger bands (20-day, ±2σ) | not available for this company yet | n/a |
| Typical daily range (% of price) | its price moves about 37.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 37.6% |
| Stretch from the 200-day average | it is trading 44.1 daily ranges below its 200-day average price (94.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 44.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 49% of its 30-day average | 0.49× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.7% |
|---|---|---|
| Open gap | it gapped 3.0% below the previous close 5 sessions ago and has not traded back through the level it left behind at 0.51 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.0% |
| Gap filled | a 2.6% gap up opened on 2026-10-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 81.9 percentage points (the stock lost 80.9% while the market gained 1.0%) | -81.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 98.8 percentage points (the stock lost 95.2% while the market gained 3.6%) | -98.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 104.5 percentage points (the stock lost 96.0% while the market gained 8.5%) | -104.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 109.0 percentage points (the stock lost 94.5% while the market gained 14.6%) | -109.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 79% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 1218.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -78.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 92% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.54 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -92.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 74% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.35 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -73.5% |
Price levels it has turned at before
KPTI last closed at $0.3586 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 19 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.79 | Resistance | 400.6% above the last close | turned there twice · 2026-07-31 to 2026-08-17 |
| $3.69 | Resistance | 927.8% above the last close | turned there three times · 2025-07-11 to 2025-08-11 |
| $4.09 | Resistance | 1040.5% above the last close | turned there twice · 2025-06-02 to 2025-06-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $1.93.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $0.4738 and $1.03 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $1.93.
This reading has stood for 17 trading days, since 2026-09-28.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$7.25 range $3.00 – $11.00; median $7.50
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KPTI
- Consensus EPS estimate-$1.32 next reporting period, as of 2026-10-17
- Estimate change, 30 days$0.00 from -$1.32, on 2026-09-12, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial doubt regarding ability to continue as a going concern due to limited liquidity and upcoming debt service obligations.","Significant history of operating losses and uncertainty regarding achievement of future profitability.","Dependence on successful clinical development and regulatory approval for new indications, particularly myelofibrosis."]
What changed in the latest 10-Q
AI-assisted comparison of KPTI's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Notes:
- The provided MD&A excerpts are identical in wording and end at the same truncated point ('Part II,'), so no changes can be identified from the available text.
Risk Factors
- Added:
- Newer filing (2026-08-13) states as of June 30, 2026, the company had approximately $65.1 million in cash, cash equivalents, and investments.
- Newer filing (2026-08-13) states existing liquidity will enable funding current operating plans into September 2026.
- Newer filing (2026-08-13) states a $15.8 million principal payment is due on September 10, 2026 under the senior secured term loan facility.
- Newer filing (2026-08-13) states if the September 10, 2026 payment is made without additional financing or waiver, cash, cash equivalents and investments will fall below the $10.0 million minimum liquidity covenant triggering a default and insufficient resources to fund operations.
- Newer filing (2026-08-13) states approximately $10.1 million of aggregate interest payments are due on September 30, 2026 under the senior secured term loan, 2028 Notes and 2029 Notes.
- Newer filing (2026-08-13) references seeking regulatory approval of selinexor in myelofibrosis as the focus of research and development and regulatory activities.
- Newer filing (2026-08-13) states the company, with assistance from Centerview Partners and other advisors, is actively evaluating a range of financing opportunities and strategic alternatives with the objective of extending cash runway, preserving strategic flexibility and maximizing long-term shareholder value as it advances its myelofibrosis program.
- Newer filing (2026-08-13) states absent additional funding or successful strategic transactions to extend cash runway beyond September 10, 2026, the company will be unable to continue as a going concern and may consider seeking protection under bankruptcy laws, liquidating assets or ceasing operations.
- Newer filing (2026-08-13) states if the company decides to seek bankruptcy protection, it expects to file earlier than when it would otherwise exhaust cash resources.
- Newer filing (2026-08-13) mentions additional cost reduction measures such as further workforce reductions, delaying, reducing or eliminating research and development programs and/or commercialization efforts, ceasing operations, liquidating assets, or seeking bankruptcy protection.
- Newer filing (2026-08-13) reports loss from operations of $22.5 million for the quarter ended June 30, 2026.
- Newer filing (2026-08-13) states the company expects to continue to incur significant expenses and operating losses as it commercializes XPOVIO in the U.S. in multiple myeloma and engages in activities to prepare for potential approval and commercialization of selinexor in myelofibrosis.
- Removed:
- Older filing (2026-05-14) states as of March 31, 2026, the company had approximately $90.9 million in cash and cash equivalents.
- Older filing (2026-05-14) states existing liquidity will enable funding current operating plans to late in the third quarter of 2026.
- Older filing (2026-05-14) describes plans to address going concern conditions by obtaining additional funding through equity offerings, debt financings and refinancings, collaborations, strategic alliances and/or licensing arrangements.
- Older filing (2026-05-14) states the company expects to evaluate opportunities to raise additional funds including through its Open Market Sale Agreement with Jefferies LLC and in connection with reporting data from ongoing Phase 3 clinical trials.
- Older filing (2026-05-14) states that if the company utilizes capital resources more quickly than anticipated or is unable to obtain additional funding or engage in strategic alternatives, it may have to significantly curtail, delay, reduce or eliminate one or more research and development programs or commercialization efforts.
- Older filing (2026-05-14) states the company has and may in the future determine to take actions to reduce spending in the near term, including reductions to its workforce.
- Older filing (2026-05-14) states if unable to continue as a going concern, the company may have to liquidate assets and may receive less than the value at which those assets are carried on its financial statements, and may determine to cease operations or file for bankruptcy protection.
- Older filing (2026-05-14) reports loss from operations of $26.8 million for the quarter ended March 31, 2026.
- Older filing (2026-05-14) describes research and development focus as developing and seeking regulatory approval of selinexor for multiple cancer indications.
- Older filing (2026-05-14) states the company expects to continue to incur significant expenses and operating losses as it commercializes XPOVIO in the U.S. and engages in activities to prepare for potential approval and commercialization of additional indications for selinexor as well as any other product candidates it develops or acquires.
- Reworded:
- Newer filing (2026-08-13) changes 'cash and cash equivalents' to 'cash, cash equivalents, and investments' in describing financial resources.
- Newer filing (2026-08-13) changes the risk factor title from 'We will need additional funding or to enter into strategic alternatives to achieve our business objectives. If we are unable to raise sufficient capital or to enter into strategic alternatives on acceptable terms to meet our needs, we may be forced to delay, reduce or eliminate our research and development programs and/or commercialization efforts' to 'We need additional funding or to enter into strategic alternatives to achieve our business objectives. If we are unable to raise sufficient capital or to enter into strategic alternatives on acceptable terms to meet our needs, we may be forced to undertake additional cost reduction measures such as further reducing operating expenses, including through additional workforce reductions, delay, reduce or eliminate our research and development programs and/or commercialization efforts or at any time we may elect to or may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code, and you may lose all or part of your investment'.
- Newer filing (2026-08-13) changes description of funding extension target from 'late in the third quarter of 2026' to 'into September 2026'.
- Newer filing (2026-08-13) changes 'FDA-approval' to 'U.S. Food and Drug Administration ("FDA") approval'.
- Newer filing (2026-08-13) changes focus from developing selinexor for multiple cancer indications to developing and seeking regulatory approval of selinexor in myelofibrosis for the capital requirements description.
- Notes:
- The newer filing text is truncated at 'While we began to generate revenue from the sales of XPOVIO in July 2019 and have received revenue from our license arran' and the older filing text is truncated at 'such as the partnership we have with Antengene Therapeutics Limited ("Antengene") for our programs across most of t', so changes after those points cannot be compared.
- Only the provided section text was compared; changes outside this excerpt were not assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 2 sells ($2097) — 1 selling insider
- Last 90 days · read to 2026-10-160 buys · 4 sells ($3477) — 2 selling insiders
- Last 180 days · read to 2026-10-160 buys · 10 sells ($38219) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-16. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KPTI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KPTI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,097,878
- Reported value $20,496,268
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about KPTI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
KPTI had 6,056,162 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
KPTI had 26.7% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.79 days to cover at the same settlement.
- Reported short interest (shares) 6,056,162
- Short interest (% of shares outstanding) 26.7%
- Prior settlement (shares) 7,865,168
- Reported change -23%
- Days to cover (reported) 4.79
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Amgen (AMGN)
- GSK (GSK)
- Johnson & Johnson (JNJ)
- Pfizer (PFE)
- Incyte (INCY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KPTI vs…
KARYOPHARM THERAPEUTICS INC is found in…
Frequently asked questions
What does KARYOPHARM THERAPEUTICS INC (KPTI) do?
Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of small-molecule medicines for cancer. Its primary technology involves XPO1 inhibition, which forces the nuclear retention of tumor suppressor proteins and oncoprotein mRNAs to trigger apoptosis in malignant cells. The company currently markets XPOVIO (selinexor) for multiple myeloma and is advancing clinical programs for myelofibrosis and other malignancies.
What sector is KARYOPHARM THERAPEUTICS INC (KPTI) in?
KARYOPHARM THERAPEUTICS INC (KPTI) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are KARYOPHARM THERAPEUTICS INC's (KPTI) competitors?
Notable peers of KARYOPHARM THERAPEUTICS INC (KPTI) include Bristol Myers Squibb, Amgen, GSK, Johnson & Johnson and Pfizer. This peer set is informational only — not financial advice.
Is KARYOPHARM THERAPEUTICS INC (KPTI) overbought or oversold right now?
KARYOPHARM THERAPEUTICS INC (KPTI) is currently in oversold territory (its 14-day RSI is 19, below 30) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KPTI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.